---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-211928"
form_type: "8-K"
ticker: "MYO"
cik: "0001369290"
company_name: "MYOMO, INC."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:29:55.611382+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Myomo Q1 revenue $10.1M (+3% YoY); net loss narrows to $3.0M; guides Q2 $10.3M-$10.8M

## Summary
- Revenue $10.1M (+3% YoY), net loss $3.0M ($0.07/sh) vs $3.5M loss ($0.08/sh) in Q1 2025.
- Gross margin expanded to 68.2% (up 100 bps); operating expenses down 1% YoY to $10.1M.
- Orders received 239 (+12% YoY); backlog 226 (+14% vs Dec 2025); pipeline adds up 7% sequentially.
- Recurring patient source revenue reached 49% of total, up from 25% a year ago.
- Q2 2026 revenue guidance $10.3M-$10.8M; FY 2026 revenue reiterated at $43M-$46M.

## SEC filing metadata
- accession: 0001193125-26-211928
- form_type: 8-K
- ticker: MYO
- cik: 0001369290
- company_name: MYOMO, INC.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369290/000119312526211928/0001193125-26-211928-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369290/000119312526211928/myo-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-211928
- JSON: https://secwatch.observer/filing/0001193125-26-211928.json
- Plain text: https://secwatch.observer/filing/0001193125-26-211928.txt

## Source-grounded claims
- claim_id: d7b762b16185e70165cbce2921803d2619f5c24e
  claim: MYOMO, INC. reported first quarter ended March 31, 2026 results: revenue $10,113,288, net income $3.0 million, EPS $0.07 per share. Guidance reaffirmed.
  evidence_excerpt: Myomo Reports First Quarter 2026 Financial and Operating Results Revenue of $10.1 million with 49% of first quarter revenue from recurring patient sources MyoPro® orders received during the quarter were up 12% year-over-year Expanded gross margin, lower operating expenses and narrowed net loss Conference call begins at 4:30pm Eastern time today BURLINGTON, Mass. (May 7, 2026) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1369290/000119312526211928/0001193125-26-211928-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.